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Francisella tularensis, a facultative intracellular bacterium, is the aetiological agent of
tularaemia. Antibiotic treatment of this zoonosis is based on the administration of a
fluoroquinolone or a tetracycline for cases with mild to moderate severity, whereas an
aminoglycoside (streptomycin or gentamicin) is advocated for severe cases. However,
treatment failures and relapses remain frequent, especially in patients suffering from
chronic lymph node suppuration. Therefore, new treatment alternatives are needed. We
have developed a dye uptake assay for determination of minimal inhibitory extracellular
concentrations (MIECs) of antibiotics against intracellular F. tularensis, and validated the
method by comparing the results obtained using a CFU-enumerating method. We also
compared MIECs with MICs of the same compounds determined using a CLSI broth
microdilution method. We tested the activity of 11 antibiotics against two clinical strains
of F. tularensis subsp. holarctica isolated in France. Both strains displayed low MICs
(≤1μg/mL) to fluoroquinolones (ciprofloxacin, levofloxacin and moxifloxacin), gentamicin,
doxycycline and rifampicin. Higher MICs (≥8μg/mL) were found for carbapenems
(imipenem and meropenem), daptomycin and linezolid. Erythromycin MICs were 4.0 and
16.0μg/mL, respectively, for the two clinical strains. MIECs were almost the same with
the two methods used. They were concordant with MICs, except for erythromycin and
linezolid (respectively, four and eight times more active against intracellular F. tularensis)
and gentamicin (four to eight times less active against intracellular F. tularensis). This study
validated the dye uptake assay as a new tool for determination of the activity of a large
panel of antibiotics against intracellular F. tularensis. This test confirmed the intracellular
activity of first-line antibiotics used for tularaemia treatment, but also revealed significant
activity of linezolid against intracellular F. tularensis.
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INTRODUCTION
Tularaemia is a zoonotic disease caused by the Gram-negative
bacterium Francisella tularensis. Two subspecies are responsi-
ble for the majority of human infections, including F. tularensis
subsp. tularensis in North America and F. tularensis subsp. holarc-
tica throughout the Northern hemisphere. The latter subspecies
is split into two biovars. Biovar I, naturally susceptible to ery-
thromycin, is found in North America and Western Europe.
Biovar II, naturally resistant to erythromycin, is found in Eastern
Europe and Asia (Keim et al., 2007). F. tularensis is highly
infectious for humans and has been classified as a category A
bioterrorism agent by the CDC (Bossi et al., 2004).
Only a few antibiotic classes are effective to treat tularaemia
patients. The aminoglycosides (streptomycin and gentamicin) are
considered the reference treatment for severe forms of the disease
(Hepburn and Simon, 2008). For mild to moderate tularaemia
cases, fluoroquinolones (ciprofloxacin, levofloxacin) and tetra-
cyclines (doxycycline) are advocated as first-line drugs (Tärnvik
and Chu, 2007). All these antibiotics have side effects and their
use should be restricted especially in pregnant women (Dentan
et al., 2013). Moreover, antibiotic treatments using a tetracycline
or a fluoroquinolone are associated with high rates of failure
and relapse (Johansson et al., 2001; Perez-Castrillon et al., 2001).
Finally, high-level resistance to macrolides, tetracyclines and flu-
oroquinolones was easily selected in vitro in F. tularensis (La Scola
et al., 2008; Gestin et al., 2010; Loveless et al., 2010; Sutera et al.,
2014), which raises some concern about the misuse of resistant
strains in the bioterrorism context or the possibility of in vivo
selection of such resistance in tularaemia patients.
F. tularensis is a slow growing, facultative intracellular bac-
terium. It replicates in the cytoplasm of macrophages (Anthony
et al., 1991; Chong and Celli, 2010) and non-phagocytic cells
(Hall et al., 2007). Both cell types are involved in tularaemia
patients, especially in the lower airways in patients suffering from
pneumonia (Horzempa et al., 2010). A number of techniques
have been developed to test the activity of antibiotics against
intracellular pathogens. In most studies, the intracellular activ-
ity of the tested antibiotic is evaluated by measuring the viable
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bacterial counts (VBCs) after antibiotic exposure compared to an
untreated control. VBCs are usually determined using the colony
forming unit (CFU)-enumeration methodology (Segreti et al.,
1996; Wright Valderas and Barrow, 2008). Because this technique
is fastidious and time consuming and not adapted for microor-
ganisms growing exclusively in eukaryotic cells, methods based on
DNA quantification using quantitative real-time PCR technology
(Boulos et al., 2004) or immunofluorescent-antibody testing (Ives
et al., 1997) have been proposed. The intracellular growth of bac-
teria can also be deduced from their cytotoxic effect in eukaryotic
cell culture systems (Edouard and Raoult, 2013), especially using
a simple dye uptake assay, as previously described for strict intra-
cellular bacteria such as Rickettsia species (Rolain et al., 1998).
This technique is based on the capacity for live cells to inter-
nalize a vital dye such as neutral red (Borenfreund and Puerner,
1985). In this system, the activity of an antibiotic is deduced from
its potential to prevent cytotoxic effects by inhibiting bacterial
multiplication.
In this study, we adapted the dye uptake assay to evaluate
the activity of several antibiotics against two clinical strains of
F. tularensis subsp. holarctica. Our first goal was to demonstrate
that this simple technique gives equivalent results compared to
the VBCs method. Because the dye uptake assay is much easier
to perform, it allowed us to screen the intracellular activity of a
large number of antibiotic compounds against several strains of F.
tularensis. This work could facilitate the search for new treatment
alternatives for tularaemia, as well as the detection of acquired
resistances to available antibiotics.
MATERIALS AND METHODS
BACTERIAL STRAINS AND CELL LINE
Two clinical strains of F. tularensis subsp. holarcticawere used: Ft6
isolated in 2007 from a blood culture and Ft24 isolated in 2009
from an axillary lymphadenopathy. Both strains were identified
to the subspecies level by sequencing the intergenic region located
between 16S and 23S RNA encoding genes (Maurin et al., 2011).
They were kept frozen in cryotubes (MastDiagnostic, Amiens,
France) at −80◦C. They were grown in a biosafety level 3 labo-
ratory, using chocolate agar supplemented with Polyvitex®(CHA-
PVX medium, bioMérieux, Marcy l’Etoile, France) incubated at
37◦C in a 5% CO2-enriched atmosphere.
We used three control strains for MIC determination:
Escherichia coliATCC25922, Pseudomonas aeruginosaATCC27853
and Staphylococcus aureus ATCC29213. They were grown on
Columbia medium supplemented with 5% sheep blood (COS
medium, bioMérieux) incubated 24 h at 37◦C with 5% CO2.
For the cell system, we used the human pulmonary diploid
fibroblastic cells MRC-5 (RD Biotech, Besançon, France). Cell
monolayers were grown in Minimum Essential Medium (MEM,
Gibco®, Life Technologies, Saint Aubin, France) supplemented
with 10% decomplemented foetal calf serum (FCS, Gibco), at
37◦C, in a 5%CO2-enriched atmosphere. These fibroblastic cells
are strictly adhesive and stop their multiplication when at con-
fluence, which enables cells proliferation control. Moreover, this
model has already been used for susceptibility testing of other
pathogens such as Legionella pneumophila (Segreti et al., 1996)
or Tropheryma whipplei (Boulos et al., 2004). Finally, F. tularensis
subsp. holarctica strains were able to efficiently infect and prolif-
erate in this model (cf. Result section).
ANTIBIOTICS
We used ciprofloxacin (Panpharma, Fougères, France), lev-
ofloxacin (Fresenius kabi, Sèvres, France), moxifloxacin
(Bayer, Puteaux, France), imipenem (Panpharma), meropenem
(Panpharma), daptomycin (Novartis, Rueil-Malmaison, France),
doxycycline (Sigma-Aldrich, Lyon, France), rifampicin (Sanofi-
Aventis, Paris, France), gentamicin (Panpharma), linezolid
(Pfizer, Paris, France) and erythromycin (Fluka, Lausanne,
Switzerland). Stock solutions of these 11 antibiotics were pre-
pared in sterile distilled water for gentamicin, ciprofloxacin and
erythromycin, and in 0.45% sodium chloride solution for the
other antibiotics, and kept frozen at −80◦C until used.
MIC DETERMINATION
MICs were determined using a microdilution method in Mueller-
Hinton (MH) broth (bioMérieux) supplemented with 2%
PolyViteX®, using a CLSI methodology (Clinical and Laboratory
Standards Institute, 2009).
Briefly, each antibiotic was diluted in MH-2%PVX to obtain
twofold serial concentrations (Table 1), and 75μL of each sus-
pension was dispensed in one well of 96-well microtiter plates.
An equal volume of a 106 bacterial suspension was added to each
well. After incubation of the plates for 48 h at 37◦C, the lowest
antibiotic concentration inhibiting visible bacterial growth was
recorded as the MIC. All experiments were run in duplicate. The
reference strains E. coli ATCC25922, P. aeruginosa ATCC27853
and S. aureus ATCC29213 were used as positive controls. Wells
receiving only MH broth were used as negative controls.
MIEC DETERMINATION
The MRC-5 cells were prepared in MEM-10% FCS at a concen-
tration of 6 × 105 cells/mL. This cell suspension was dispensed
(100μL per well) in flat-bottom 96-well microtiter plates, and
incubated 16 h at 37◦C in a 5% CO2-enriched atmosphere to
Table 1 | Ranges of antibiotic concentrations tested for determination
of MICs (broth microdilution method) and MIECs (dye uptake assay)
for 11 antibiotics against Francisella tularensis subsp. holarctica.
Antibiotics Antibiotic targets MIC (µg/mL) MIEC (µg/mL)
Gentamicin Ribosome 0.032–16 0.064–32
Ciprofloxacin Type II topoisomerases 0.001–0.5 0.004–2.0
Levofloxacin Type II topoisomerases 0.001–0.5 0.004–2.0
Moxifloxacin Type II topoisomerases 0.001–0.5 0.004–2.0
Doxycycline Ribosome 0.032–16 0.032–16
Erythromycin Ribosome 0.25–128 0.25–128
Imipenem Cell wall 0.25–128 0.25–128
Meropenem Cell wall 0.25–128 0.25–128
Linezolid Ribosome 0.064–32 0.064–32
Rifampicin RNA polymerase 0.004–2.0 0.016–8.0
Daptomycin Cytoplasmic membrane 0.5–256 0.5–256
MIC, minimum inhibitory concentration; MIEC, minimum inhibitory extracellular
concentration.
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obtain confluent cell monolayers. In parallel, a 1-McFd stan-
dard suspension of each F. tularensis strain tested was grown for
24 h in brain-heart infusion broth (BHI, bioMérieux) supple-
mented with 2% PVX, at 37◦C, in 5%CO2. For each strain, the
bacterial suspension obtained was adjusted to 0.5 McF standard
by adding BHI-2%PVX, and further diluted in MEM-10% FCS
to achieve a bacterial inoculum of 1.2 × 105 bacteria/50μL of
medium (i.e., 2.4 × 106 bacteria/mL). The cell monolayers were
infected by replacing the supernatant with 50μL of the previ-
ously prepared bacterial suspension. The plates were incubated
at 37◦C, in 5% CO2 for 3 h to allow internalization of bacte-
ria into MRC-5 cells. Cell monolayers were then washed in pH
7.2 sterile phosphate buffer saline (PBS, Gibco) and re-incubated
for 1 h (37◦C, 5% CO2,)in MEM-10% FCS medium containing
5μg/mL of gentamicin in order to eliminate extracellular bacte-
ria. At that time, the intracellular bacterium inoculum (referred to
as the primary intracellular inoculum) was determined using the
CFU-enumeration method (see below). After 3 additional washes
with PBS, infected MRC-5 monolayers were incubated (37◦C, 5%
CO2) in MEM-10% FCS medium containing twofold serial con-
centrations of the tested antibiotic (Table 1). MIECs were read
after 1 or 5 days incubation of the plates at 37◦C, in 5% CO2for
the CFU method and the dye uptake assay, respectively. All assays
included a F. tularensis positive growth control (infected MRC-
5 cells with no antibiotic) and two negative controls (uninfected
MRC-5 with no antibiotic or with the antibiotic at the maximum
concentration tested). The activity of antibiotics against intracel-
lular F. tularensis was then evaluated in parallel using two meth-
ods: the dye uptake assay and CFU counting. All experiments were
run in duplicates to confirm results.
Dye uptake assay
After incubation of the plates, the cell supernatants were removed
and replaced with 50μL of 0.15% neutral red dye (Sigma-
Aldrich) in PBS, pH 5.5. The plates were incubated 1 h at 37◦C
in 5% CO2 to allow penetration of the dye into the cells. The
excess dye was then removed by three washes in PBS, pH 6.5. The
red staining of cell monolayers was visually evaluated in compar-
ison to positive (T+, MRC-5 monolayer infected at MOI 200:1
without antibiotics) and negative controls (T-ATB, uninfected
MRC-5 monolayer incubated with the highest concentration of
the antibiotic tested). A staining score of 1 corresponded to com-
plete lysis of the cell monolayer, i.e., T+ control. A staining score
of 4 corresponded to full preservation of the cell monolayer,
i.e., T-ATB control. Scores 2 and 3 corresponded to intermedi-
ate color intensities (Figure 1). The MIEC was defined as the
minimum extracellular concentration of the antibiotic tested
allowing prevention of a F. tularensis cytotoxic effect (staining
score of 4).
CFU counts
After incubation of the plates, the cell supernatants were removed
and replaced with 200μL of 1% saponin solution (ProLabo®,
Leuven, Belgium). The plates were incubated 15min at room
temperature to allow disruption of the eukaryotic cell membranes
and release of intracellular bacteria into the cell supernatant. After
homogenisation, 1, 10, and 100μL of the bacterial suspension
of each well were plated on CHA-PVX media. CFU counts were
determined after 48 h incubation of the CHA-PVX plates at 37◦C,
in 5% CO2. The same procedure was used to determine the pri-
mary intracellular bacterial inoculum, as mentioned above. Thus
FIGURE 1 | Image of a dye uptake assay for the Ft24 strain.
∗, antibiotic concentrations in the well (μg/mL); T-ATB, uninfected
MRC-5 monolayer incubated with the highest concentration of the
antibiotic tested; GEN, gentamicin; IMI, imipenem; MER,
meropenem; LIN, linezolid; CIP, ciprofloxacin; LEV, levofloxacin;
MOX, moxifloxacin.
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the activity of antibiotics was deduced from their capacity to
completely inhibit bacterial growth, i.e., CFU counts after antibi-
otic exposure ≥ CFU counts of the primary intracellular bacterial
inoculum.
RESULTS
DYE UPTAKE ASSAY VALIDATION
We first tested the activity of ciprofloxacin and doxycycline
against intracellular F. tularensis Ft6 strain, using both the CFU
and dye uptake assays (Figure 2). For drug-free controls, the
mean increase in intracellular bacterial loads after 24 h incuba-
tion of cultures was between 2.41 and 3.43 log CFU/well (data
not shown). As for ciprofloxacin (Figure 2A), the CFU method
determined the MIEC to be 0.125μg/mL. The same method also
revealed that ciprofloxacin induced a two-log reduction of bac-
terial loads at concentrations above the MIEC. The dye uptake
assay showed complete destruction of the cell monolayers after 5
days incubation of cultures (score = 1) at ciprofloxacin concen-
trations up to 0.032μg/mL, a score of 3 at 0.064μg/mL, and a
score of 4 for concentrations ≥ 0.125μg/mL. Thus, ciprofloxacin
MIEC was the same for the dye uptake and CFU count assays.
For doxycycline (Figure 2B), the MIECs were 0.25μg/mL and
0.5μg/mL using the CFU and dye uptake assays, respectively.
Doxycycline only induced a lower (<1 log) reduction in bacterial
counts after 24 h incubation. Also, a reduction in the dye uptake
scores was observed for doxycycline concentrations ≥ 2μg/mL,
suggesting a toxic effect of this compound against MRC-5 cells at
these concentrations.
MICs AND MIECs OF 11 ANTIBIOTICS AGAINST F. TULARENSIS FT6
AND FT24 STRAINS
Both strains displayed low MICs for gentamicin, fluoro-
quinolones (ciprofloxacin, levofloxacin and moxifloxacin), doxy-
cycline and rifampicin (Table 2). Erythromycin was less effective,
with four times higher MIC for the Ft24 strain compared to the
Ft6 strain. The carbapenems (imipenem, meropenem) and dap-
tomycin had no inhibitory activity against F. tularensis. Similar
MIC and MIEC values were obtained for fluoroquinolones,
doxycycline and rifampicin. Gentamicin was less effective against
intracellular F. tularensis, with MIECs four to eight times higher
than MICs. In contrast, erythromycin and linezolid displayed
improved activity against intracellular F. tularensis. MIECs were
four to eight times lower than MICs for erythromycin and eight
times lower than MICs for linezolid.
DISCUSSION
We adapted a dye uptake assay previously used to test the antibi-
otic susceptibilities of strict intracellular pathogens (Rolain et al.,
1998) to investigate the activity of antibiotics against the intracel-
lular form of the facultative intracellular bacterium F. tularensis.
This test is safer than traditional CFU-based assays because it does
not need manipulation of large quantities of culture dishes of this
highly infectious agent. Although the test should be performed in
a biosafety level 3 laboratory, the intracellular activity of several
Table 2 | Activities of 11 antibiotics against two clinical strains (Ft6
and Ft24) of F. tularensis subsp. holarctica determined using a broth
microdilution method and a dye uptake assay, respectively.
MIC (µg/mL) MIEC (µg/mL)
Ft6 Ft24 Ft6 Ft24
Gentamicin 0.25 0.5 2 2
Ciprofloxacin 0.032 0.032 0.064 0.064
Levofloxacin 0.064 0.064 0.064 0.064
Moxifloxacin 0.125 0.125 0.125 0.125
Doxycycline 0.5 1 0.5 0.5
Erythromycin 4 16 1 2
Imipenem >128 >128 >128 >128
Meropenem >128 >128 >128 >128
Linezolid 8 8 1 1
Rifampicin 0.5 0.5 0.5 0.5
Daptomycin >256 >256 >256 >256
MIC, minimum inhibitory concentration; MIEC, minimum inhibitory extracellular
concentration.
FIGURE 2 | Comparison of results obtained with the CFU enumeration
and dye uptake assays for intracellular activity of ciprofloxacin (A) and
doxycycline (B) against F. tularensis subsp. holarctica stain Ft6. Squares,
CFU counts 24 h post-infection (CFU/well); triangles, dye uptake assay (score
1–4); horizontal line, 1 h post-infection intracellular bacterial load (CFU/well) as
determined by the CFU-enumeration method (results of one experiment).
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compounds against a large panel of type A and type B F. tularen-
sis strains could be easily achieved. We first validated this new
assay by comparing the results obtained for two antibiotics against
two clinical strains of F. tularensis subsp. holarctica when using
either the dye uptake assay or a traditional method of VBC
determination using CFU methodology. We found a high cor-
relation between MIECs determined using both methods. This
was not unexpected since, in our model, F. tularensis multi-
plication led to complete lysis of cell monolayers. In contrast,
inhibition of intracellular bacterial growth prevented F. tularensis
cytolytic effects. Complete monolayer lysis was revealed using the
live stain neutral red. This molecule is commonly used for cyto-
toxicity (Borenfreund and Puerner, 1985) or vacuolation assays
(Cover et al., 1991), as it rapidly accumulates in lysosomes after
penetration in viable cells by diffusion through the cytoplasmic
membrane. It has been previously shown that the presence of
weak bases (Ohkuma and Poole, 1981) or bacterial compound
(Cover et al., 1991) influences vacuoles production level. Crystal
violet has been used for similar experiments with the advantage
that this stain binds to chromatin and thus color intensitymay not
vary according to the antibiotic used (Brasaemle and Attie, 1988).
However, we observed an increase in neutral red uptake in cells
exposed to antibiotics facilitating interpretation of results due to
higher contrast between lysed and unlysedmonolayers (Figure 1).
For standardization, we framed each assay with controls used as
visual cut-off for independent interpretation for each antibiotic
(i.e., Materials and Methods section).
We then evaluated the extracellular and intracellular activ-
ity of 11 antibiotic compounds against the same two clinical
strains of F. tularensis, respectively, using a CLSI broth microdi-
lution method and the dye uptake assay developed. The broth
microdilution method for antibiotic susceptibility testing of F.
tularensis remains fastidious and the results are poorly predic-
tive of the clinical situation for some antibiotics (Valade et al.,
2008). Numerous controls are also needed, such as the use of
non-fastidious control strains to check antibiotic activity in more
standardized conditions. MIC results were consistent with pre-
vious studies. As expected, the carbapenems, which belong to
the beta-lactams family, were not effective against F. tularensis
(Georgi et al., 2012). Both strains were susceptible to antibiotics
used as first-line treatment of tularaemia, including three fluoro-
quinolone compounds, doxycycline and gentamicin (Urich and
Petersen, 2008; Valade et al., 2008). Rifampicin was also highly
effective against F. tularensis in vitro. Erythromycin was less effec-
tive, although we tested type B biovar I strains of F. tularensis,
which was consistent with previous studies (Gestin et al., 2010;
Georgi et al., 2012). The new compounds daptomycin (a lipopep-
tide) and linezolid (an oxazolidinone) were either ineffective or
poorly effective against extracellular F. tularensis. To our knowl-
edge, linezolid has only been tested against Francisella sp. strains
using MIC test strips, with inconsistent results between stud-
ies. MIC ranges were 2–16μg/mL for North American strains
tested using Mueller-Hinton supplemented with 1% IsovitaleX
(Johansson et al., 2002) and 0.5–2.0μg/mL for Turkish strains
from central Anatolia tested using glucose/cysteine blood agar
(GCBA) plates supplemented with 9% sheep blood (Yes¸ilyurt
et al., 2011), whereas the MIC90 was 32μg/mL for Hungarian
strains tested using modified Francis agar plates (Kreizinger
et al., 2012). These discrepancies may represent true differences
in linezolid susceptibilities among F. tularensis strains of differ-
ent geographic origin, but may also reflect poor standardization
of the methods used. Valade et al. (2008) previously demon-
strated that MIC test strips gave different results when using
different agar media, and that the results obtained with this
method were poorly correlated to those obtained using the ref-
erence agar dilution method, especially for nalidixic acid and
rifampicin.
We found ciprofloxacin and doxycycline had similar inhibitory
activity against extracellular and intracellular F. tularensis. These
two antibiotic classes are concentrated within eukaryotic cells
(Hof, 2003) and are used as reference treatments for infectious
diseases caused by intracellular pathogens (Rolain et al., 1998;
Wright Valderas and Barrow, 2008). However, using the CFU
method, we found a more pronounced bactericidal effect of
ciprofloxacin as compared to doxycycline against F. tularensis
strains grown in MRC-5 cells, which confirms previously pub-
lished data using macrophage-like cells (Maurin et al., 2000).
These findings are consistent with the current recommendation
of the use of ciprofloxacin and doxycycline as first-line treatment
of tularaemia (Johansson et al., 2000; Scheftel et al., 2010; Maurin
et al., 2011). In our model, the aminoglycoside gentamicin was
four to eight times less effective against the intracellular form of
F. tularensis. Previous experiments have shown that gentamicin
displays a bactericidal activity against intracellular F. tularen-
sis, but prolonged exposure of infected cells to this antibiotic is
needed because of its slow penetration and concentration within
eukaryotic cells (Maurin and Raoult, 2001). Whereas strepto-
mycin was considered the referenced treatment of tularaemia
(Tärnvik and Chu, 2007), gentamicin has been recently associated
with treatment failures and relapses (Kaya et al., 2012).
Regarding antibiotics not currently recommended for treat-
ment of tularaemia, three situations were observed. Rifampicin
displayed similar extracellular and intracellular activities. This
antibiotic is not used for treatment of tularaemia because of con-
cern about selection of resistant mutants (Bhatnagar et al., 1994).
Daptomycin and the carbapenems were not effective against the
extra- and intracellular forms of the two F. tularensis strains
tested. The beta-lactams are usually considered unreliable for
treatment of tularaemia (Cross and Jacobs, 1993). Although F.
tularensis may harbor a class A beta-lactamase (Antunes et al.,
2012), mechanisms of resistance to carbapenems in this species
need further investigation. To our knowledge, susceptibility to
imipenem has been reported only for three biovar II strains of
F. tularensis subsp. holarctica (including the LVS strain) (Tomaso
et al., 2005). Lee et al. (1991) reported a case of tularaemia with
favorable progression after 14-day treatment with imipenem.
Finally, erythromycin and linezolid were more active when tested
in the MRC-5 cell system. MIECs were eight times lower than
MICs, suggesting that these compounds could concentrate in
the intracellular compartment of F. tularensismultiplication. The
same observation was previously reported for azithromycin and
the LVS strain of F. tularensis (Ahmad et al., 2010). Erythromycin,
like other macrolides, can concentrate within acidic compart-
ments of eukaryotic cells (especially lysosomes) because of their
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low base nature (Carlier et al., 1987). However, their intracellu-
lar activity may be reduced owing to their protonation at acidic
pH (Goldman et al., 1990). The macrolides are not considered
a safe alternative for tularaemia patients (Enderlin et al., 1994),
but recent case reports indicate that azithromycin may be useful
in pregnant women with mild disease caused by type B biovar
I strains of F. tularensis (Dentan et al., 2013). More surpris-
ingly, linezolid displayed significant activity against intracellular
F. tularensis in vitro. This oxazolidinone is currently used for treat-
ment of infections caused by multi-drug-resistant Gram-positive
bacterial species, such as S. aureus, Streptococcus pneumoniae and
Enterococcus sp. Interestingly, an additive effect of the combina-
tion of linezolid and gentamicin was reported against S. aureus
(Grohs et al., 2003). Linezolid is not active against aerobic Gram-
negative bacteria such as enterobacterial and Pseudomonas sp.
(Leclercq, 2010). On the other hand, linezolid did not accumu-
late in THP-1 human macrophage cells (Lemaire et al., 2011).
Thus, the mechanism of action of linezolid against intracellular
F. tularensis should be further investigated.
In conclusion, we adapted a dye uptake assay in order to eval-
uate the activity of antibiotics against intracellular F. tularensis.
This test would facilitate screening of the activity of new com-
pounds against this fastidious, facultative intracellular bacterium
in the search for new therapeutic alternatives for tularaemia. Also,
because the proposed technique is much easier to perform than
the traditional CFUmethodology, it may help standardize antibi-
otic susceptibility testing for F. tularensis strains. Finally, this
study highlights the potential usefulness of linezolid as a ther-
apeutic alternative for tularaemia patients, especially in case of
failure or relapses after administration of current first-line antibi-
otics. In vitro results obtained with this drug warrant further
investigation in animal models.
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